Patent details

EP4249512 Title: STABLE ANTIBODY FORMULATION

Basic Information

Publication number:
EP4249512
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP231779737
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
STABLE ANTIBODY FORMULATION
French Title of Invention:
FORMULATION STABLE D'ANTICORPS
German Title of Invention:
STABILE ANTIKÖRPERFORMULIERUNG
SPC Number:

Dates

Filing date:
23/03/2018
Grant date:
23/07/2025
EP Publication Date:
27/09/2023
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
23/07/2025
EP B1 Publication Date:
23/07/2025
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
23/03/2038
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
16/07/2025
 
 

Name:
Regeneron Pharmaceuticals, Inc.
Address:
777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States (US)

Agent

Name:
NLO
From:
24/07/2025
Address:
P.O. Box 29720, 2502 LS The Hague, Netherlands (NL)
To:

Inventor

1

Name:
HU, Qingyan
Address:
United States (US)

2

Name:
LIU, Dingjiang
Address:
United States (US)

Priority

Priority Number:
201762482270 P
Priority Date:
06/04/2017
Priority Country:
United States (US)

Classification

IPC classification:
A61K 9/00; A61K 39/00; A61K 47/18; A61K 47/26; C07K 16/28;

Publication

European Patent Bulletin

Issue number:
202530
Publication date:
23/07/2025
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
31/03/2027
Annual Fee Number:
10
Annual Fee Amount:
131 Euro
Expected Payer:
Last Annual Fee Payment Date:
19/02/2026
Last Annual Fee Paid Number:
9
Last Annual Fee Paid Amount:
115 Euro
Payer:
ANAQUA SERVICES (ANC. SGA2)
Filing date Document type Number of pages
23/07/2025 Power Of Attorney 1
24/07/2025 Outgoing Correspondence 1